The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2023

Filed:

Dec. 13, 2019
Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Akihisa Kaneko, Shizuoka, JP;

Yuki Iwayanagi, Shizuoka, JP;

Hidetomo Kitamura, Shizuoka, JP;

Yoshinobu Higuchi, Shizuoka, JP;

Hiroaki Matsushita, Shizuoka, JP;

Ryosuke Mihara, Tokyo, JP;

Yumi Yamamoto, Tokyo, JP;

Tomohisa Saito, Tokyo, JP;

Keiko Hirokawa, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/24 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C07K 16/24 (2013.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01);
Abstract

In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.


Find Patent Forward Citations

Loading…